Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madhav Prasad Yadav

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Nuclear Medicine|May 18, 2016
Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle ApplicationChandrasekhar Bal, Madhav Prasad Yadav, Sanjana Ballal
EJNMMI Research|February 7, 2019
Concomitant <sup>177</sup>Lu-DOTATATE and capecitabine therapy in malignant paragangliomasMadhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal
Clinical Nuclear Medicine|November 17, 2023
Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body ParagangliomaMadhav Prasad Yadav, Shobhana Raju, Sanjana Ballal, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2021
Efficacy and safety of <sup>225</sup>Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot studyMadhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, et al.
EJNMMI Research|October 28, 2020
[<sup>177</sup>Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety resultsMadhav Prasad Yadav, Sanjana Ballal, Marian Meckel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world studySwayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2022
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant <sup>225</sup>Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome StudySanjana Ballal, Madhav Prasad Yadav, Madhavi Tripathi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 11, 2019
Broadening horizons with <sup>225</sup>Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to <sup>177</sup>Lu-DOTATATE PRRT: first clinical experience on the efficacy and safetySanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, et al.
Clinical Nuclear Medicine|December 5, 2023
Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot ExperienceSwayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Evaluation of [<sup>68</sup>Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [<sup>68</sup>Ga]Ga-DOTA-NOC PET/CTDivya Yadav, Sanjana Ballal, Madhav Prasad Yadav, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Nuclear Medicine|May 18, 2016
Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle ApplicationChandrasekhar Bal, Madhav Prasad Yadav, Sanjana Ballal
EJNMMI Research|February 7, 2019
Concomitant <sup>177</sup>Lu-DOTATATE and capecitabine therapy in malignant paragangliomasMadhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal
Clinical Nuclear Medicine|November 17, 2023
Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body ParagangliomaMadhav Prasad Yadav, Shobhana Raju, Sanjana Ballal, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2021
Efficacy and safety of <sup>225</sup>Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot studyMadhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, et al.
EJNMMI Research|October 28, 2020
[<sup>177</sup>Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety resultsMadhav Prasad Yadav, Sanjana Ballal, Marian Meckel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world studySwayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2022
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant <sup>225</sup>Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome StudySanjana Ballal, Madhav Prasad Yadav, Madhavi Tripathi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 11, 2019
Broadening horizons with <sup>225</sup>Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to <sup>177</sup>Lu-DOTATATE PRRT: first clinical experience on the efficacy and safetySanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, et al.
Clinical Nuclear Medicine|December 5, 2023
Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot ExperienceSwayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Evaluation of [<sup>68</sup>Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [<sup>68</sup>Ga]Ga-DOTA-NOC PET/CTDivya Yadav, Sanjana Ballal, Madhav Prasad Yadav, et al.
Pageof 4